Table Of Content

AUTHOR INDEX Volume 73 • 1997 Abe, N. See Ashizawa, N. Inada, 1. See Satoh, H. Abiko, Y. See Hoque, A.N.E. Inada, Y. See Kanagawa, R. Akaike, A. See Kume, T. Inagaki, C. See Tanabe, T. Akaike, N. See Ashizawa, N. Inatomi, N. See Satoh, H. Aotsuka, T. See Ashizawa, N. Inoue, H. See Arai, 1. Arai, I., Shimazoe, T., Shibata, S., Inoue, H., Yoshimatsu, A. Inukai, T. See Okada, M. and Watanabe, S. Ishii, T. See Niioka, S. Dopamine release in sensitized rats 243 Isohama, Y., Kumanda, Y., Tanaka, K., Kai, H., Takahama, K. Asano, K. See Katayama, K. and Miyata, T. Asano, S. See Satoh, H. Dexamethasone and surfactant phosphatidylcholine secretion Ashizawa, N., Yoshida, M., Sugiyama, Y., Akaike, N., 163 Ohbayashi, S., Aotsuka, T., Abe, N., Fukushima, K. Ito, N. See Kashiwa, M. and Matsuura, A. Iwasaki, T. See Nakamura, K. Novel aldose reductase inhibitor, GP-1447 133 Atsuta, Y., See Matsunaga, M. Kadota, S. See Matsumoto, K. Kai, H. See Isohama, Y. Chang, C.-W., Ko, F.-N., Su, M.-J., Wu, Y.-C. and Teng, C.-M. Kakiuchi, M., Ohashi, T., Musoh, K., Kawamura, K., Ocoteine, an oi-adrenoceptor antagonist 207 Morikawa, K. and Kato, H. Central effects of antiallergic agents 291 Domoto, FI. See Moriyama, M. Kakuta, H. See Kashiwa, M. Kamata, K., Hayashi, T. and Umeda, F. Endo, T. See Taniguchi, H. CPA and pathology 247 Eto, K. See Kanda, M. Kanagawa, R., Wada, T., Sanada, T., Ojima, M. and Inada, Y. Etoh, H. See Matsunaga, M. Regional hemodynamic effects ofTCV-116 185 Kanai, K. See Matsunaga, M. Folkman, J. See Satoh, H. Kanda, M., Eto, K., Tanabe, N., Sugiyama, A., Hashimoto, K. Fujii, T. See Yamaguchi, N. and Ueno, A. Fujimoto, K. See Yamaguchi, N. Aldose reductase on diabetic M receptors 221 Fujita, T. See Kume, T. Kaneko, S. See Kume, T. Fukuda, T. See Katayama, K. Kangawa, K. See Okamura, T. Fukushima, K. See Ashizawa, N. Kashiwa, M., Masuyama, Y., Miyauchi, H., Uchida, T., Fukuta, T. See Nitta, A. Naganuma, S., Kakuta, H., Terada, M., Kiriyama, T., Furukawa, M. See Ikeda, K. Matsuda, K., Ito, N., lizumi, Y. and Takenaka, T. Furuno, K. See Moriyama, M. ACAT inhibitor and diarrhea 41 Katayama, K., Asano, K., Haga, K. and Fukuda, T. Geng, M.-Y., Saito, H. and Nishiyama, N. The binding affinity of azasetron 357 Neuroprotective effect of ifenprodil 97 Kato, H. See Kakiuchi, M. Gomita, Y. See Moriyama, M. Kato, K. See Satoh, H. Kato, M. See Matsumoto, Y. Haga, K. See Katayama, K. Kato, R. See Nishikawa, K. Hara, A. See Hoque, A.N.E. Kawamura, K. See Kakiuchi, M. Hasegawa, T. See Nitta, A. Kawasaki, H. See Moriyama, M. Hashimoto, K. See Kanda, M. Kawashima, K. See Yamaguchi, N. Hashizume, H. See Hoque, A.N.E. Kawazura, H., Takahashi, Y., Shiga, Y., Shimada, F., Ohto, N. Hata, F. See Niioka, S. and Tamura, A. Hayashi, K., Nagamatsu, T., Oka, T. and Suzuki, Y. Effect of MS-153 on brain ischemia 317 Antinephritic effect of ONO-1301 73 Kiriyama, T. See Kashiwa, M. Hayashi, N. SeeOkada, M. Kishi, M. See Niioka, S. Hayashi, T. See Kamata, K. Ko, F.-N. See Chang, C.-W. Hoque, A.N.E., Hoque, N., Hara, A., Hashizume, H., Ichihara, K. Kobayashi, S. See Tanaka, M. and Abiko, Y. Kohchiyama, H. See Kume, T. K-7259 on ischemia and reperfused heart 365 Kohno, S. See Matsumoto, K. Hoque, N. See Hoque, A.N.E. Koike, K. See Takayanagi, I. Koike, Y. See Yamamoto, Takatsugu Ichihara, K. See Hoque, A.N.E. Kojima, S. Ichimaru, Y. See Mori, T. CGRP and NANC transmission 255 lizumi, Y. See Kashiwa, M. Kometani, M. See Okada, M. Ikeda, K., Furukawa, M., Tanno, N., Yamaya, M. Kumai, T. See Tanaka, M. and Takasaka, T. Kumanda, Y. See Isohama, Y. Cl“ secretion by Sai-rei-to 29 Kume, E. See Taniguchi, H. VI Author Index Kume, T., Kohchiyama, H., Nishikawa, H., Maeda, T., Ogawa, R. See Tanabe, T. Kaneko, S., Akaike, A., Noda, N. and Fujita, T. Ohashi, M. See Matsumoto, Y. Neuroprotection by fetal calf serum 371 Ohashi, T. See Kakiuchi, M. Kurihara, H. See Shinosaki, T. Ohbayashi, S. See Ashizawa, N. Kuromi, H. and Seino, S. Ohizumi, Y. Inhibition of glucose effect by suramin 179 Pharmacological tools from natural resources 263 Kurose, H. See Sato, Y. Ohto, N. See Kawazura, H. Ohyanagi, M. See Nakamura, K. Maeda, R. See Satoh, H. Ojima, M. See Kanagawa, R. Maeda, T. See Kume, T. Oka, T. See Hayashi, K. Masukawa, T. and Nakanishi, K. Okada, M., Hayashi, N., Kometani, M., Nakao, K. and Inukai, T. Circadian variation of convulsion 175 Effect of estradiol on TST and FST 93 Masuyama, Y. See Kashiwa, M. Okamura, T. See Shiraishi, S. Matsuda, K. See Kashiwa, M. Okamura, T., Zhang, J.-X., Kangawa, K. and Toda, N. Matsumoto, K., Kohno, S., Tezuka, Y., Kadota, S. Inhibition by AM of adrenergic function 259 and Watanabe, H. Okayasu, A. See Takayanagi, I. Angelica root and social isolation stress 353 Osaki, T. See Yoneda, K. Matsumoto, Y., Kato, M., Tamada, Y., Mori, H. and Ohashi, M. Otani, H. See Tanabe, T. Effects of Sho-saiko-to on keratinocytes 333 Matsunaga, M., Uemura, Y., Yonemoto, Y., Kanai, K., Etoh, H., Saito, H. See Geng, M.-Y. Tanaka, S., Atsuta, Y., Nishizawa, Y. and Yamanishi, Y. Sanada, T. See Kanagawa, R. Transdermal eperisone as muscle relaxant 215 Sanaka, M. See Yamamoto, Takatsugu Matsuura, A. See Ashizawa, N. Sato, F. See Satoh, H. Mineshita, S. See Yamamoto, Takatsugu Sato, J. See Misawa, M. Misaw'a, M. and Sato, J. Sato, T. See Moriyama, M. NO and airway hyperresponsiveness 125 Sato, Y., Kurose, H. and Nagao, T. Mishima, K. See Tanabe, T. Desensitization of cardiac ^S-adrenoceptors 325 Miyata, T. See Isohama, Y. Satoh, H., Asano, S., Maeda, R., Murakami, I., Inada, I., Sato, F. Miyauchi, H. See Kashiwa, M. and Shino, A. Mori, H. See Matsumoto, Y. Prevention of ulcer relapse by bFGF 229 Mori, T., Murase, K., Tanaka, J. and Ichimaru, Y. Satoh, H., Sato, F., Takami, K. and Szabo, S. Interaction between Dp and Ds-agonists 251 Ulcerative colitis by sulfhydryl blocker 299 Morikawa, K. See Kakiuchi, M. Satoh, H., Shino, A., Sato, F., Asano, S., Murakami, I., Moriyama, M., Yamashita, S., Furuno, K., Sato, T., Domoto, H., Inatomi, N., Nagaya, H., Kato, K., Szabo, S. and Folkman, J. Yamatogi, Y., Kawasaki, H. and Gomita, Y. Role of bFGF in healing of gastric ulcers 59 Lactation and plasma phenobarbital concentrations 191 Satoh, M. See Takayanagi, I. Murakami, I. See Satoh, H. Seino, S. See Kuromi, H. Murase, K. See Mori, T. Shibasaki, K., Takizawa, K., Uchida, W. and Takenaka, T. Murayama, T. See Yamada, T. Ca^^ antagonist with ^-blocking activity 113 Musoh, K. See Kakiuchi, M. Shibata, S. See Arai, I. Shiga, Y. See Kawazura, H. Nabeshima, T. See Nitta, A. Shikano, T. See Taniguchi, H. Nagamatsu, T. See Hayashi, K. Shimada, F. See Kawazura, H. Naganuma, S. See Kashiwa, M. Shimakura, K. See Yamamoto, Takatsugu Nagao, T. See Sato, Y. Shimazoe, T. See Arai, I. Nagasaki, M. See Taniguchi, H. Shino, A. See Satoh, H. Nagaya, H. See Satoh, H. Shinosaki, T., Takagawa, 1., Sunagawa, N., Yonetani, Y. Nagumo, H. See Nishikawa, K. and Kurihara, H. Nakamura, K., Ohyanagi, M. and Iwasaki, T. Effect of lisinopril on PAN nephrosis 337 mRNA for ,5-adrenoceptor in ischemia 23 Shiraishi, S., Okamura, T. and Toda, N. Nakanishi, K. See Masukawa, T. ^preceptor in hepatic arterial relaxation 101 Nakao, K. See Okada, M. Su, M.-J. See Chang, C.-W. Nakaya, S. See Tanaka, M. Sugiyama, A. See Kanda, M. Niioka, S., Takeuchi, T., Kishi, M., Ishii, T., Nishio, H., Sugiyama, Y. See Ashizawa, N. Takewaki, T. and Hata, F. Sunagawa, N. See Shinosaki, T. NANC relaxation in rat jejunum 155 Suzuki, T. See Yamaguchi, N. Nishikawa, H. See Kume, T. Suzuki, Y. See Hayashi, K. Nishikawa, K., Yamamoto, S., Nagumo, H. and Kato, R. Szabo, S. See Satoh, H. PKCC activation by Ca^*-induced differentiation 171 Nishio, H. See Niioka, S. Takagawa, I. See Shinosaki, T. Nishiyama, N. See Geng, M.-Y. Takahama, K. See Isohama, Y. Nishizawa, Y. See Matsunaga, M. Takahashi, Y. See Kawazura, H. Nitta, A., Fukuta, T., Hasegawa, T. and Nabeshima, T. Takami, K. See Satoh, H. Toxicity of ,5-amyloid protein in vivo 51 Takasaka, T. See Ikeda, K. Noda, N. See Kume, T. Takayanagi, I., Koike, K., Satoh, M. and Okayasu, A. Nomura, Y. See Yamada, T. Drug receptor mechanisms 1 Author Index vii Takenaka, T. See Kashiwa, M. Wada, T. See Kanagawa, R. -See Shibasaki, K. Wang, L. See Yamamoto, Takatsugu Takeuchi, T. See Niioka, S. Warashina, A. Takewaki, T. See Niioka, S. Indomethacin effects on CA secretion 197 Takizawa, K. See Shibasaki, K. Watanabe, H. See Matsumoto, K. Tamada, Y. See Matsumoto, Y. Watanabe, M. See Tanaka, M. Tamura, A. See Kawazura, H. Watanabe, S. See Arai, I. Tanabe, N. See Kanda, M. Wu, Y.-C. See Chang, C.-W. Tanabe, T., Otani, H., Mishima, K., Ogawa, R. and Inagaki, C. Oxyradical production in synovial cells 347 Yamada, T., Murayama, T. and Nomura, Y. Tanaka, J. See Mori, T. Muscarinic receptors on thymocytes 311 Tanaka, K. See Isohama, Y. Yamaguchi, N., Fujimoto, K., Fujii, T., Suzuki, T. Tanaka, M., Nakaya, S., Watanabe, M., Kumai, T., Tateishi, T. and Kawashima, K. and Kobayashi, S. Antihypertensive effect of YM358 in SHRSP 83 Estrogen replacement on aorta ACE activity 361 Yamamoto, S. See Nishikawa, K. Tanaka, S. See Matsunaga, M. Yamamoto, Takatsugu, Wang, L., Shimakura, K., Sanaka, M., Taniguchi, H., Yomota, E., Kume, E., Shikano, T., Endo, T. Koike, Y. and Mineshita, S. and Nagasaki, M. Angiotensin and pulmonary edema 33 Effect of T-0632 on acute pancreatitis 105 Yamamoto, Tetsuya See Yoneda, K. Tanno, N. See Ikeda, K. Yamanishi, Y. See Matsunaga, M. Tateishi, T. See Tanaka, M. Yamashita, S. See Moriyama, M. Teng, C.-M. See Chang, C.-W. Yamatogi, Y. See Moriyama, M. Terada, M. See Kashiwa, M. Yamaya, M. See Ikeda, K. Tezuka, Y. See Matsumoto, K. Yomota, E. See Taniguchi, H. Toda, N. See Okamura, T. Yoneda, K., Yamamoto, Tetsuya, Ueta, E. and Osaki, T. - See Shiraishi, S. Suppression of azelastine of NF-<rB activation 145 Yonemoto, Y. See Matsunaga, M. Uchida, T. See Kashiwa, M. Yonetani, Y. See Shinosaki, T. Uchida, W. See Shibasaki, K. Yoshida, M. See Ashizawa, N. Uemura, Y. See Matsunaga, M. Yoshimatsu, A. See Arai, I. Ueno, A. See Kanda, M. Ueta, E. SeeYoneda, K. Zhang, J.-X. See Okamura, T. Umeda, F. See Kamata, K. SUBJECT INDEX Volume 73 • 1997 Acyl-CoA:cholesterol acyltransferase Cholesterol 41 Ifenprodil 97 (ACAT) inhibitor 41 Cholinergic neuron 51 Indomethacin 197 Adenylyl cyclase 325 Cholinergic neurotransmission 125 In situ hybridization 23 Adrenal chromaffin cell 197 Ms-Cholinoceptor 1 Intercollicular decerebrated rat rigidity model Adrenergic neurotransmission 259 Circadian variation 175 215 ai-Adrenoceptor 1 Cl~ secretion 29 Interleukin-1« 333 «i-Adrenoceptor antagonist 207 Colon 255 lodoacetamide 299 ,5-Adrenoceptor 23, 163, 325 Convulsion 175 Ion channel 263 ^1-Adrenoceptor 101 Cultured keratinocyte 333 Irreversible ,5-adrenoceptor antagonist 325 ^-Adrenoceptor antagonist 325 Cyclopiazonic acid 247 Ischemia 23, 317, 365 Adrenomedullin 259 Cytokine 145 Isozyme 171 Afterload 33 Airway hyperresponsiveness 125 Di-receptor agonist 251 Jejunum 155 Aldose reductase inhibitor 133, 221 Dj-receptor agonist 251 Alveolar type 11 cell 163 Depressor action 259 K-7259 (b/, A'^'-bis[4-(3,4,5-trimethoxyphenyl)- Alzheimer’s disease 51 Desensitization of ,5-adrenoceptor 325 butyljhomopiperazine dihydrochloride) Amphoteric compound 291 Diabetes 221,247 365 Amyloid protein 51 Diabetic neuropathy 133 K" channel 155 Angelicae radix 353 Diarrhea 41 Keratinocyte 333 Angiogenesis 59 Dinitrophenylated (DNP)-/lsccra 125 Angiotensin II 33 DNA fragmentation 311 Lactation 191 Angiotensin II receptor antagonist 185 Dopamine release 243 Learning and memory 51 Angiotensin ATi-receptor antagonist 83 Drug receptor mechanism 1 Lisinopril 337 Angiotensin-converting enzyme (ACE) 361 Losartan 33 Anionic charge barrier 337 Enalapril 185 Antiallergic agent 291 Endothelium-derived relaxing factor 247 M3-cholinoceptor 1 Anti-glomerular basement membrane (GBM) Enoxacin 175 Metabotropic glutamate receptor 243 nephritis 73 Eperisone hydrochloride 215 Methamphetamine-induced sensitization Antihypertensive effect 83,113 Estrogen replacement therapy 361 243 Antiinflammatory drug 299 N-Ethylmaleimide 299 Middle cerebral artery occlusion 317 Aorta 361 Excitation-contraction coupling 263 Motor activity 251 Apamin-sensitive K * channel 155 Excitotoxic disorder 97 Motor nerve conduction velocity 133 Autocrine growth 333 MS-153 ((/?)-(— )-5-methyl-1 -nicotinoyl-2- Azasetron 357 Fetal calf serum 371 pyrazoline) 317 Azelastine hydrochloride 145 bFGF mutein CS23 (TGP-580) 59, 229 Mucociliary transport 29 Fibroblast growth factor (basic) (bFGF) Muscarine 197 Basal secretion 29 59, 229 Muscarinic receptor 221,311 Basic fibroblast growth factor (bFGF) Focal cerebral ischemia 317 Muscle relaxant activity 215 59, 229 Forced swimming test 93 ^i-blocker 113 Nephrosis 337 /3 cell 179 Gastric ulcer 59 NF-zrB 145 Bladder dome 221 Gastric ulcer relapse 229 NIH Image program 215 Blood flow 185 Glial fibrillary acidic protein 51 Nitrergic dysfunction 125 Bradykinin 197 Glomerular sclerosis 337 Nitric oxide 125, 155, 371 Glucocorticoid 163 Nitric oxide synthase 145 Ca^^-induced differentiation 171 Glucose 179 Nonadrenergic, noncholinergic (NANC) Caerulein 105 Glutamate 371 relaxation 155 Calcitonin gene-related peptide (CGRP) Nonadrenergic noncholinergic (NANC) trans¬ 255 Heart failure 33 mission 255 Calcium antagonist 113 Hepatic artery 101 Norepinephrine 101 CAMP 73 Hippocampal cultured neuron 97 Candesartan cilexetil (TCV-116) 185 Histamine Hi-receptor 291 Ocoteine 207 Cardiac ventricle 325 Histamine H2-receptor antagonist 229 ONO-1301 (t7,8-dihydro-5-[(£)-[[a-(3- Cassytha filiformis 207 HSR-609 (3-[4-(8-fluoro-5,11 -dihydro- pyridyl)benzylidene]aminooxy]ethyl]-l- Cataract formation 133 benz [b] oxepino [4,3-b] pyridin-11 - naphtyloxyjacetic acid) 73 Catecholamine secretion 197 ylidene-piperidino]propionic acid Otitis media with effusion 29 Central nervous system penetraion 291 dihydrate) 291 Ovariectomy 93 Cerebroprotection 317 5-HT3 receptor 357 Oxyradical production 347 ,5-Chloroethylamine 1 Hybridization (in silu) 23 Cholecystokinin (CCK)a receptor 105 Hydrocortisone 311 Pancreatic duct ligation 105 Subject Index ix Pancreatitis 105 Signal transduction 1 TGP-580 (bFGF mutein CS23) 59, 229 Pentobarbital sleep 353 Small intestine 357 Therapeutic window 317 Percutaneous administration 215 Social isolation stress 353 Thoracic aorta 207 Pharmacokinetics 191 Sorbitol 133 Thymocyte 311 Pharmacological tool 263 Spontaneously hypertensive rat 185 Phenobarbital 191 Stress 353 Ulcerative colitis model 299 Physiologically active substance 263 Striatal dopamine release 243 Plasma concentration 191 Stroke-prone spontaneously hypertensive rats Vascular cell adhesion molecule 73 Polyol pathway 221 83 Protein kinase C 171, 347 Sulfhydryl blocker 299 Working rat heart 365 Protein phosphorylation 263 Suramin 179 Pulmonary edema 33 Synovial cell 347 YM17E (1,3-bis[[ 1 -cycloheptyl-3-(p-dimeth- Pulmonary surfactant 163 ylaminophenyl)ureido]methyl]benzene Puromycin aminonucleoside nephrosis 337 T-0509 ((—)-{R)-1 -(3,4-dihydroxyphenyl)-2- dihydrochloride) 41 [(3,4-dimethoxyphenethyl)amino]ethanol YM358 (2,7-diethyl-5-[[2-(l//-tetrazole-5- Radiotelemetry 83 hydrochloride) 325 yl)biphenyl-4-y Ijmethyl] -5//-pyrazolo [1,5- Rigidity model (rat) 215 T-0632 (sodium (S)-l-(2-fluorophenyl)-2,3-di- Z?][l,2,4]triazole potassium salt) 83 mRNA 23 hydro-3-[(3-isoquinolinylcarbonyl)amino]- YM430 (4(((S)-2-hydroxy-3-phenoxy- RNase protection assay 163 6-methoxy-2-oxo-l//-indole-3-propanoate) propyl)amino)butyl methyl 2,6-dimethyl- 105 ((S)-4-(m-nitrophenyl))-1,4-dihydro- Sho-saiko-to 333 Tail skin temperature 93 pyridine-3,5-dicarboxylate) 113 Short-circuit current 29 TCV-116 (candesartan cilexetil) 185 j L_